[go: up one dir, main page]

BRPI0508655A - composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante - Google Patents

composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante

Info

Publication number
BRPI0508655A
BRPI0508655A BRPI0508655-8A BRPI0508655A BRPI0508655A BR PI0508655 A BRPI0508655 A BR PI0508655A BR PI0508655 A BRPI0508655 A BR PI0508655A BR PI0508655 A BRPI0508655 A BR PI0508655A
Authority
BR
Brazil
Prior art keywords
erlichiosis
canine
prevention
composition
dog
Prior art date
Application number
BRPI0508655-8A
Other languages
English (en)
Inventor
Thomas Jay Hess
Yu-Wei Chiang
Hsien-Jue Chu Steve
Liangbiao Hu George
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508655A publication Critical patent/BRPI0508655A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçãO DE VACINA; MéTODO PARA à PREVENçãO OU ATENUAçãO DE ERLIQUIOSE CANINA EM UM CãO; E COMPOSIçãO DE ESTIRPE DESAFIANTE. A presente invenção proporciona uma composição de vacina segura e eficaz que compreende; uma quantidade imunizante eficaz de uma bacterina de Ehrlichia canis; um veículo farmacologicamente aceitável; e uma quantidade imunogenicamente estímulante de um sistema adjuvante que consiste essencialmente em um agente indutor de resposta de anticorpo e um agente indutor de resposta imunitária mediada por célula. A presente invenção proporciona também um método para a prevenção ou atenuação de erliquiose canina em cães.
BRPI0508655-8A 2004-03-11 2005-03-10 composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante BRPI0508655A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55235004P 2004-03-11 2004-03-11
PCT/US2005/007875 WO2005087803A1 (en) 2004-03-11 2005-03-10 A canine vaccine for protection against ehrlichiosis

Publications (1)

Publication Number Publication Date
BRPI0508655A true BRPI0508655A (pt) 2007-08-14

Family

ID=34965712

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508655-8A BRPI0508655A (pt) 2004-03-11 2005-03-10 composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante

Country Status (22)

Country Link
US (2) US20050202046A1 (pt)
EP (2) EP2338903A1 (pt)
JP (1) JP2008500962A (pt)
KR (1) KR20060129475A (pt)
CN (1) CN1930185A (pt)
AR (1) AR048030A1 (pt)
AT (1) ATE530566T1 (pt)
AU (1) AU2005222396A1 (pt)
BR (1) BRPI0508655A (pt)
CA (1) CA2558047A1 (pt)
CO (1) CO5721012A2 (pt)
CY (1) CY1112120T1 (pt)
DK (1) DK1723170T3 (pt)
ES (1) ES2374278T3 (pt)
IL (1) IL177860A0 (pt)
ME (1) ME01252B (pt)
PL (1) PL1723170T3 (pt)
PT (1) PT1723170E (pt)
RS (1) RS52188B (pt)
SI (1) SI1723170T1 (pt)
WO (1) WO2005087803A1 (pt)
ZA (1) ZA200607547B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115840A1 (en) * 1998-11-30 2002-08-22 Walker David H. Homologous 28-kilodaltion immunodominant protein genes of Ehrlichia canis and uses thereof
EP2077856B1 (en) * 2006-11-03 2015-08-12 Intervet International BV Canine lyme disease vaccine
CN104083757A (zh) 2007-04-06 2014-10-08 武田疫苗公司 用于活的减毒病毒的方法和组合物
US8361480B2 (en) 2007-09-11 2013-01-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Attenuated ehrlichiosis vaccine
US9051557B2 (en) * 2007-09-12 2015-06-09 Intervet International B.V. Method for continuously culturing Ehrlichia canis
BRPI0817090A2 (pt) 2007-09-12 2014-11-25 Intervet Int Bv Método de cultura e uma espécie bacteriana da família anaplasmataceae, e, composição.
EP2045816A1 (en) * 2007-10-01 2009-04-08 Paul Scherrer Institut Fast readout method and swiched capacitor array circuitry for waveform digitizing
EP2588133B1 (en) 2010-07-02 2018-01-17 Intervet International B.V. Vaccine against ehrlichia canis and associated methods
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
AU2013329025B2 (en) 2012-10-11 2019-07-04 Zoetis Services Llc Peptides, devices, and methods for the detection of Ehrlichia antibodies
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
US12390516B2 (en) 2017-07-31 2025-08-19 Kansas State University Research Foundation Vaccines against tick-borne diseases
BR112021001420A2 (pt) 2018-07-27 2021-05-04 Research Development Foundation polipeptídeos imunogênicos quiméricos
EP3996741A1 (en) * 2019-07-12 2022-05-18 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
WO2025006564A1 (en) 2023-06-26 2025-01-02 Research Development Foundation Immunoreactive peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192679A (en) * 1990-05-03 1993-03-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Growing ehrlichia species in a continuous cell line
EP0465204B1 (en) * 1990-07-06 2000-09-20 American Home Products Corporation Vaccine against Lyme disease
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
WO1998042743A1 (en) * 1997-03-24 1998-10-01 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
US6043085A (en) 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
US6432649B1 (en) 2000-08-25 2002-08-13 The Ohio State University Research Foundation Methods for detecting Ehrlichia canis and Ehrlichia chaffeensis in vertebrate and invertebrate hosts
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Also Published As

Publication number Publication date
JP2008500962A (ja) 2008-01-17
ZA200607547B (en) 2008-06-25
IL177860A0 (en) 2006-12-31
EP1723170A1 (en) 2006-11-22
CO5721012A2 (es) 2007-01-31
SI1723170T1 (sl) 2012-01-31
PT1723170E (pt) 2012-01-10
US20060188524A1 (en) 2006-08-24
EP1723170B1 (en) 2011-10-26
AU2005222396A1 (en) 2005-09-22
CY1112120T1 (el) 2015-11-04
RS52188B (sr) 2012-10-31
ATE530566T1 (de) 2011-11-15
ME01252B (me) 2013-06-20
PL1723170T3 (pl) 2012-03-30
EP2338903A1 (en) 2011-06-29
DK1723170T3 (da) 2011-12-05
AR048030A1 (es) 2006-03-22
CN1930185A (zh) 2007-03-14
ES2374278T3 (es) 2012-02-15
KR20060129475A (ko) 2006-12-15
US20050202046A1 (en) 2005-09-15
US7635481B2 (en) 2009-12-22
WO2005087803A1 (en) 2005-09-22
CA2558047A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
BRPI0508655A (pt) composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante
CR10726A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
Hotez et al. Advancing a vaccine to prevent hookworm disease and anemia
Kreiss et al. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations
CO5700790A2 (es) Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina
CY1116904T1 (el) Εμβολιο
MX2010007815A (es) Composiciones inmunogenicas de mycoplasma hyopneumoniae contra pcv2 y metodos para producir composiciones de este tipo.
IL185897A (en) Use of influenza virus or antigenic agent derived from the first influenza virus strain and adjuvant of water emulsion for the preparation of a vaccine for the protection against influenza strain caused by a variant influenza when the water emulsion contains squalene, alpha-tocopherol and emulsifier
AR059688A1 (es) Uso de alfa - toxina para tratar y prevenir las infecciones por staphylococcus
BRPI0408635A (pt) emulsões de óleo em água microfluidizadas e composições de vacinas
CL2008001806A1 (es) Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
CL2011000877A1 (es) Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino.
ITGE20060088A1 (it) Protezione e dispositivo di guida per cavo o simili
TW200744631A (en) Lawsonia vaccine and methods of use thereof
EA201001478A1 (ru) Вакцина
ITGE20060089A1 (it) Protezione e dispositivo di guida per cavo o simili
UY32930A (es) Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas
MX362429B (es) Metodo para proporcionar inmunidad protectora contra cepas de leptospira heterologas.
WO2006117538A3 (en) Assays for diagnosis of tuberculosis and uses thereof
BR0115095A (pt) Composição de vacina, e, método para induzir uma resposta imune em um ruminante para prover proteção imune que reduz a severidade de ou infecção por a. marginale
MX2022000525A (es) Vacunas contra la ehrlichia y composiciones inmunogenicas.
BRPI0408249A (pt) vacinas bovinas com adjuvante
EP2433648A3 (en) Vaccine comprising an oil in water emulsion adjuvant
PH12012500933A1 (en) Actinobacillus suis antigens

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B25A Requested transfer of rights approved

Owner name: PAH W LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS W LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements